HyperSight Scans for Pediatric Cancer
(Peds Ethos Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new imaging method called HyperSight to improve radiation therapy for children with certain types of cancer. The aim is to determine if using HyperSight scans twice a week can help doctors create better radiation plans by detecting changes in the body during treatment. Children aged 18 or under who are already receiving radiation for non-brain tumors and can manage daily activities fairly well might be suitable candidates. The study will compare the new adapted plans with the usual ones to assess which is more effective. As an unphased trial, this study provides a unique opportunity for patients to contribute to innovative research that could enhance future cancer treatments.
What prior data suggests that HyperSight CBCT imaging is safe for pediatric patients?
Research has shown that HyperSight CBCT imaging is generally safe. Previous studies have compared images from HyperSight CBCT to regular CBCT, finding that HyperSight provides clearer images, aiding doctors in planning better treatments.
However, CBCT, like other imaging methods, involves radiation exposure. Some studies suggest a risk of developing cancer from this radiation, particularly in children and women, as children are more sensitive to radiation than adults. Despite this, the benefits of clear imaging often outweigh the risks, especially when it enhances treatment decisions.
Overall, while HyperSight CBCT is usually well-tolerated, the potential radiation risk should be considered. Discuss any concerns about radiation exposure with a healthcare provider.12345Why are researchers excited about this trial?
Researchers are excited about HyperSight scans because they offer a cutting-edge approach to improving the accuracy of imaging in pediatric cancer treatment. Unlike traditional imaging techniques, HyperSight combines traditional radiation therapy with advanced twice-weekly CBCT (Cone-Beam Computed Tomography) scans. This method aims to provide clearer, more detailed images, which could lead to better-targeted treatments and potentially improved outcomes for young patients. By enhancing imaging precision, HyperSight has the potential to revolutionize how doctors monitor and adjust cancer treatments, making it a promising advancement in pediatric oncology.
What evidence suggests that HyperSight CBCT imaging is effective for pediatric cancer?
Studies have shown that HyperSight CBCT imaging greatly enhances the quality of CT scans. This advanced method reduces metal artifacts and clarifies images compared to standard techniques. Research indicates that dose calculations using HyperSight CBCT are highly accurate, differing by less than 1% from traditional CT scans. Additionally, this technology captures images swiftly, in just six seconds, which benefits adaptive radiation therapy. In this trial, participants will receive standard-of-care radiation therapy along with twice-weekly HyperSight CBCT scans. Overall, these improvements suggest that HyperSight CBCT could effectively enhance radiation treatment planning by providing clearer and more precise images.15678
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Radiation Treatment
Participants receive standard-of-care radiation therapy with twice-weekly HyperSight CBCT scans for adaptive radiation planning using the Ethos platform.
Follow-up
Participants are monitored for safety and effectiveness after treatment as part of standard care.
What Are the Treatments Tested in This Trial?
Interventions
- HyperSight
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants will receive standard-of-care radiation therapy, with the addition of twice-weekly HyperSight CBCT scans.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University Health Network, Toronto
Lead Sponsor
Citations
Hypersight and Ethos In Pediatric Radiotherapy
This outcome measures how tumor and organ-at-risk (OAR) anatomy changes during pediatric radiation therapy using HyperSight CBCT. From baseline ...
HyperSight CBCT image quality and metal artifact reduction ...
This study evaluates the quality of HyperSight CBCT images compared to current clinical standards: TrueBeam CBCT for image guidance and fan‐beam ...
HyperSight Imaging for Cancer · Info for Participants
Research has shown that HyperSight Imaging, which participants in this trial will receive, greatly improves the quality of cone beam CT (CBCT) scans. Studies ...
Feasibility of HyperSight CBCT for adaptive radiation therapy
In this study, the accuracy of dose calculations performed on HyperSight CBCT was found to be within 1% of CTsim calculations for pelvic and ...
Feasibility of automated AI-based contouring and stable ...
This study evaluated segmentation accuracy, efficiency, and radiomic feature stability for manual (MD), artificial intelligence-based (AI), ...
Projected lifetime cancer risk from cone-beam computed ...
Females and children show a higher risk of developing cancer due to radiation from CBCT. Clinicians should be aware of the increased cancer risk due to ...
HyperSight CBCT Imaging for Cancer
Research has shown that HyperSight CBCT imaging is safe for people. Previous studies compared the image quality of HyperSight CBCT to regular CBCT, focusing on ...
8.
kevinobrienorthoblog.com
kevinobrienorthoblog.com/three-dimensional-cbct-imaging-pretty-pictures-but-a-risk-of-cancer/Three-dimensional CBCT imaging: Pretty pictures but a risk ...
A future increase in the use of CBCT images could cause 361 cancers, mostly in children. What did I think? This paper's results and the ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.